Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Children's Minnesota to Launch Epic, Giving Families a More Connected Way to Manage Care with MyChartMINNEAPOLIS & ST. PAUL, Minn., October 02, 2026--Children’s Minnesota will go live with Epic, its new electronic health record, on Oct. 3, 2026, across its hospitals, clinics and specialty care sites.
- MarketsandMarketsClinical Trial Supplies Market worth $8.95 billion by 2031 - Exclusive Report by MarketsandMarkets™According to MarketsandMarkets™, the Clinical Trial Supplies Market is projected to reach USD 8.95 billion by 2031 from USD 5.60 billion in 2026, at a CAGR of 8.9% during the forecast period. Browse 420 market data Tables and 50 Figures...
- CRISPR Therapeutics AGCRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company’s Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026.
- SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that a late-breaking abstract evaluating the results of the post-approval SAVE Registry data has been accepted for a special late-breaker poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2026 meeting, taking place in Denver, CO, October 21 – 25, 2026.
- Pheast Therapeutics to Present Preclinical Data on PHST001, a First-in-class Antibody Targeting CD24, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual MeetingREDWOOD CITY, Calif., October 02, 2026--Pheast Therapeutics, a clinical-stage biotechnology company advancing next-generation targeted therapies for cancer, today announced an upcoming poster presentation of preclinical data on PHST001 at the 41st Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place from November 4-8 in Phoenix, AZ. PHST001 is a first-in-class anti-CD24 macrophage checkpoint inhibitor designed to restore immune recognition in the tumor microenvironment and is
- Obesity Action CoalitionOAC Calls on Cigna to Listen to Employees and Restore GLP-1 CoverageCompanies: The Cigna GroupThe Obesity Action Coalition (OAC) is calling on Cigna to listen to its employees and reconsider its decision to end coverage of GLP-1 medications for weight management. In June, Cigna notified more than 50,000 U.S. employees that its health plan...
- Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural ValidationPatent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall
- Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 GuidanceIntegra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance.
- SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and HospitalsMajor Institutional Formulary Win Expands Arbli™’s Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially
- Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1 diabetes
- Emboline, Inc.Emboline Announces First U.S. Commercial Use of the Emboliner® Embolic Protection SystemMilestone marks the beginning of U.S. commercialization following FDA 510(k) clearance — Emboline, Inc., a medical technology company developing next-generation embolic protection technology, today announced the first commercial use of its...
- Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan BIntegra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the launch of a proposed $600 million seven-year Senior Secured Term Loan B as part of a broader refinancing transaction.